MA35414B1 - Formulations de vaccin parenteral contre un norovirus - Google Patents

Formulations de vaccin parenteral contre un norovirus

Info

Publication number
MA35414B1
MA35414B1 MA36741A MA36741A MA35414B1 MA 35414 B1 MA35414 B1 MA 35414B1 MA 36741 A MA36741 A MA 36741A MA 36741 A MA36741 A MA 36741A MA 35414 B1 MA35414 B1 MA 35414B1
Authority
MA
Morocco
Prior art keywords
norovirus
vaccine formulations
parenteral vaccine
formulations against
relates
Prior art date
Application number
MA36741A
Other languages
English (en)
Inventor
Charles Richardson
Robert F Bargatze
Paul M Mendelman
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35414(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MA35414B1 publication Critical patent/MA35414B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions de vaccin parentéral, à dose unique, qui comportent des mélanges de particules de type virus norovirus monovalent. L'invention concerne également des procédés pour conférer une immunité protectrice contre des infections par le norovirus à un sujet humain par l'administration de telles compositions.
MA36741A 2011-07-11 2014-02-06 Formulations de vaccin parenteral contre un norovirus MA35414B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11
PCT/US2012/046222 WO2013009849A1 (fr) 2011-07-11 2012-07-11 Formulations de vaccin parentéral contre un norovirus

Publications (1)

Publication Number Publication Date
MA35414B1 true MA35414B1 (fr) 2014-09-01

Family

ID=47506489

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36741A MA35414B1 (fr) 2011-07-11 2014-02-06 Formulations de vaccin parenteral contre un norovirus

Country Status (29)

Country Link
US (5) US9801934B2 (fr)
EP (3) EP3299030B1 (fr)
JP (2) JP6208659B2 (fr)
KR (1) KR102096937B1 (fr)
CN (3) CN103874507A (fr)
AU (2) AU2012282658B2 (fr)
BR (1) BR112014000656A2 (fr)
CA (1) CA2841356C (fr)
CL (1) CL2014000082A1 (fr)
CR (2) CR20190540A (fr)
DK (1) DK3299030T3 (fr)
DO (2) DOP2014000004A (fr)
EA (3) EA035442B1 (fr)
EC (1) ECSP14013201A (fr)
ES (2) ES2926487T3 (fr)
GE (1) GEP201706668B (fr)
HK (3) HK1198136A1 (fr)
IL (1) IL230356B (fr)
MA (1) MA35414B1 (fr)
MX (1) MX356586B (fr)
MY (1) MY170746A (fr)
PE (1) PE20140845A1 (fr)
PH (1) PH12018501515A1 (fr)
PL (2) PL3299030T3 (fr)
SG (1) SG10201605644WA (fr)
TN (1) TN2014000008A1 (fr)
UA (1) UA117732C2 (fr)
WO (1) WO2013009849A1 (fr)
ZA (2) ZA201401012B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2601969B1 (fr) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Formulations de vaccin contre un norovirus
JP2010539192A (ja) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
PL3299030T3 (pl) 2011-07-11 2022-12-05 Takeda Vaccines, Inc. Pozajelitowe preparaty szczepionek przeciw norowirusowi
JP2016533172A (ja) 2013-10-03 2016-10-27 タケダ ワクチン，インコーポレイテッド 細胞株からラブドウイルスを検出および除去する方法
WO2015093452A1 (fr) 2013-12-16 2015-06-25 武田薬品工業株式会社 Microaiguille
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
US11306292B2 (en) * 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3752185A1 (fr) 2018-02-15 2020-12-23 Icon Genetics GmbH Composition immunogène et vaccin pour générer une réponse immunitaire à un norovirus
WO2019231712A1 (fr) * 2018-05-29 2019-12-05 Stc.Unm Compositions de particules de type viral et leurs procédés d'utilisation
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
US20230285534A1 (en) 2020-01-08 2023-09-14 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
JPWO2022210742A1 (fr) 2021-03-29 2022-10-06
US20240238401A1 (en) 2021-05-21 2024-07-18 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
CA2133339A1 (fr) 1992-04-08 1993-10-09 Jennifer S. Rota Glycoproteines du virus morbilleux sauvage : vaccin et methode de depistage
JPH08500250A (ja) 1992-09-07 1996-01-16 ベイラー・カレッジ・オブ・メディシン ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬
WO1994021292A1 (fr) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
CA2189882C (fr) 1994-05-16 2005-09-20 Kathrin U. Jansen Vaccins contre le papillomavirus
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
PL336715A1 (en) 1997-04-08 2000-07-03 Merck & Co Inc Stabilised formulation of human papilloma virus
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
SK2232001A3 (en) 1998-08-14 2001-08-06 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
AU770809B2 (en) 1998-12-17 2004-03-04 Merck Sharp & Dohme Corp. Synthetic virus-like particles with heterologous epitopes
EP1150712B1 (fr) 1999-02-05 2008-11-05 Merck & Co., Inc. Formulations vaccinales contre le virus du papillome humain
KR100771402B1 (ko) 1999-06-22 2007-10-30 국립감염증연구소장이 대표하는 일본국 Ｓｒｓｖ 검출 킷트
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20040121465A1 (en) 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CA2482448C (fr) 2002-04-11 2014-07-08 Medimmune Vaccines, Inc. Conservation de matieres bio-actives au moyen de mousse lyophilisee
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2003103605A2 (fr) 2002-06-07 2003-12-18 Large Scale Biology Corporation Ensemble de vaccins adaptable et plate-forme d'administration de vaccins
US20040005338A1 (en) 2002-06-20 2004-01-08 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
CA2514667C (fr) 2003-01-30 2013-01-08 Chiron Corporation Vaccin contre la grippe contenant un adjuvant
EP1599188A2 (fr) 2003-02-20 2005-11-30 Becton, Dickinson and Company FORMULATIONS EN POUDRE DE L'ENTROTOXINE STAPHYLOCOCCIQUE B (<SB>R</SB>SEB) PRODUIT PAR SECHAGE PAR PULVERISATION POUR UNE VACCINATION AMELIOREE
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
EP1670824A2 (fr) 2003-09-24 2006-06-21 Montana State University Anticorps monoclonaux de norovirus et peptides
US7795242B2 (en) 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
EA015907B1 (ru) 2004-10-20 2011-12-30 Санофи Пастер Байолоджикс Ко. Рекомбинантный флавивирус и его применение
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
RU2007129840A (ru) 2005-01-05 2009-02-20 Филадельфия Хелт Энд Эдьюкейшн Корпорейшн Д/Б/А Дрексел Юниверсити Колледж Оф Медисин (Us) Средства доставки, биологически активные вещества и вирусные вакцины
EP1846439A2 (fr) 2005-01-31 2007-10-24 The Johns Hopkins University Utilisation de sequences consensus en tant qu'antigene de vaccin dans le but d'ameliorer la reconnaissance de variants viraux virulents
CN101180312A (zh) 2005-02-18 2008-05-14 诺华疫苗和诊断公司 来自尿路病原性大肠杆菌的免疫原
DK1868642T3 (da) 2005-03-18 2013-06-24 Cytos Biotechnology Ag Katte-allergenfusionsproteiner og anvendelser deraf
EP1885394A4 (fr) 2005-06-01 2009-10-21 Dow Global Technologies Inc Production de particules multivalentes semblables à des virus
EP1736538A1 (fr) 2005-06-21 2006-12-27 Cytos Biotechnology AG Procédé pour la purification préparative de particules pseudo-virales (VLPs)
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
EP2601969B1 (fr) * 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Formulations de vaccin contre un norovirus
ES2480491T3 (es) 2006-12-06 2014-07-28 Novartis Ag Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
HUE028605T2 (en) * 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
AU2008299589B2 (en) 2007-09-12 2014-06-26 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP2010539192A (ja) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
EP3382011A1 (fr) 2008-08-08 2018-10-03 Takeda Vaccines, Inc. Particules de type virus comprenant des séquences d'acides aminés de capside composites pour une réactivité croisée améliorée
JP2012515752A (ja) * 2009-01-22 2012-07-12 ファーマシーネ，インコーポレイテッド 安定なワクチン組成物とその使用方法
EP2942062A1 (fr) * 2009-02-10 2015-11-11 Novartis AG Posologies de vaccin antigrippal pour souches liées à une pandémie
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
WO2011091279A2 (fr) * 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Présentation d'antigènes hétérologues ciblés sur des pseudo-particules virales du calicivirus
KR20130108983A (ko) * 2010-05-26 2013-10-07 셀렉타 바이오사이언시즈, 인크. 커플링되지 않은 애주번트를 갖는 나노담체 조성물
PL3299030T3 (pl) 2011-07-11 2022-12-05 Takeda Vaccines, Inc. Pozajelitowe preparaty szczepionek przeciw norowirusowi
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US10975149B2 (en) 2015-12-16 2021-04-13 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
JP7181862B2 (ja) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
JP2021522798A (ja) 2018-05-03 2021-09-02 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞
WO2020041192A1 (fr) 2018-08-20 2020-02-27 Takeda Vaccines, Inc. Formulations de ppv
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
MX2021009742A (es) 2019-02-15 2021-12-10 Editas Medicine Inc Celulas asesinas naturales (nk) modificadas para inmunoterapia.

Also Published As

Publication number Publication date
US10675341B2 (en) 2020-06-09
NZ710919A (en) 2017-12-22
EP3299030A1 (fr) 2018-03-28
JP2014520852A (ja) 2014-08-25
GEP201706668B (en) 2017-05-25
BR112014000656A2 (pt) 2017-02-14
UA117732C2 (uk) 2018-09-25
CA2841356C (fr) 2022-03-01
EP2731621A1 (fr) 2014-05-21
ZA201500915B (en) 2016-06-29
EP3299030B1 (fr) 2022-06-08
CN108567975A (zh) 2018-09-25
PL3299030T3 (pl) 2022-12-05
HK1199202A1 (en) 2015-06-26
EA201792407A2 (ru) 2018-03-30
DOP2014000004A (es) 2014-10-31
CR20190540A (es) 2022-04-04
US20180185468A1 (en) 2018-07-05
EA202090699A3 (ru) 2020-11-30
US11701420B2 (en) 2023-07-18
WO2013009849A1 (fr) 2013-01-17
CR20140069A (es) 2014-06-27
PE20140845A1 (es) 2014-08-03
SG10201605644WA (en) 2016-09-29
TN2014000008A1 (en) 2015-07-01
HK1215154A1 (zh) 2016-08-19
US20210085778A1 (en) 2021-03-25
AU2015200836B2 (en) 2016-08-25
HK1198136A1 (en) 2015-03-13
EP2731621A4 (fr) 2015-03-25
CN103874507A (zh) 2014-06-18
CL2014000082A1 (es) 2014-07-04
MY170746A (en) 2019-08-27
MX2014000411A (es) 2014-08-26
EP4112074A1 (fr) 2023-01-04
AU2012282658A1 (en) 2013-03-14
US9867876B2 (en) 2018-01-16
ECSP14013201A (es) 2014-05-31
ES2926487T3 (es) 2022-10-26
PL2731621T3 (pl) 2018-10-31
CN105031637A (zh) 2015-11-11
US9801934B2 (en) 2017-10-31
EA201490258A1 (ru) 2014-05-30
US20130273102A1 (en) 2013-10-17
CA2841356A1 (fr) 2013-01-17
PH12018501515B1 (en) 2019-02-04
US20230338503A1 (en) 2023-10-26
NZ620865A (en) 2015-08-28
EA035442B1 (ru) 2020-06-17
JP6613259B2 (ja) 2019-11-27
AU2015200836A1 (en) 2015-03-12
DOP2022000030A (es) 2022-06-30
EP2731621B1 (fr) 2017-11-01
JP2017214357A (ja) 2017-12-07
KR102096937B1 (ko) 2020-04-03
AU2012282658B2 (en) 2014-11-27
PH12018501515A1 (en) 2019-02-04
EA029470B1 (ru) 2018-03-30
EA201792407A3 (ru) 2018-07-31
US20160000899A1 (en) 2016-01-07
DK3299030T3 (da) 2022-09-05
KR20140066160A (ko) 2014-05-30
IL230356B (en) 2019-05-30
EA202090699A2 (ru) 2020-07-31
ZA201401012B (en) 2015-05-27
MX356586B (es) 2018-06-05
ES2656527T3 (es) 2018-02-27
JP6208659B2 (ja) 2017-10-04

Similar Documents

Publication Publication Date Title
MA35414B1 (fr) Formulations de vaccin parenteral contre un norovirus
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
PH12015501156A1 (en) Pharmaceutical compositions
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
MD20200093A2 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
NZ721952A (en) Delayed release compositions of linaclotide
MX2013001677A (es) Formulaciones estables de linaclotida.
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
EA201391515A1 (ru) Инактивированная вакцина вируса денге
AR061894A1 (es) Vacunas para malaria
WO2012075362A3 (fr) Modulateurs du récepteur cxcr4 de la chimiokine et leurs utilisations
WO2014205199A3 (fr) Compositions et méthodes de potentialisation de la réponse immunitaire, de stimulation de l'immunothérapie et d'augmentation de la puissance d'un vaccin
EA201490222A1 (ru) Комбинированные составы на основе дарунавира
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
MD20140094A2 (ro) Spiro [2.4]heptani pentru tratamentul infecţiilor cauzate de Flaviviridae
EA201490223A1 (ru) Составы на основе дарунавира
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
EA201590678A1 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
MA35303B1 (fr) Vaccin contre la rhinite equine
IN2013MU01177A (fr)
EA032913B1 (ru) Препараты производных пиримидиндиона